Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: May 3, 2026

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 24, 2014

Scl-86, a marker antigen for diffuse scleroderma.

W J van Venrooij, S O Stapel, H Houben

The Journal of Clinical Investigation

|March 1, 1985

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Treatment Outcome, Duration, and Costs: A Comparison of Performance Indicators Using Data from Eight Mental Health Care Providers in The Netherlands.

Administration and policy in mental health·2017

Same author

[Prerequisites for a new health care model for elderly people with multiple morbidities: results and conclusions from 3 years of research in the PRISCUS consortium].

Zeitschrift fur Gerontologie und Geriatrie·2012

Same author

Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation endproducts.

Rheumatology (Oxford, England)·2008

Same author

Accumulation of advanced glycation endproducts in patients with systemic lupus erythematosus.

Rheumatology (Oxford, England)·2007

Same author

Opposed independent effects and epistasis in the complex association of IRF5 to SLE.

Genes and immunity·2007

Same author

Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus.

Lupus·2006

Same journal

Extracellular matrix reprogramming by the YAP/TAZ- TGF-ß2 axis drives immune exclusion in cholangiocarcinoma models.

The Journal of clinical investigation·2026

Same journal

Tumor cell-derived extracellular vesicles foster the immunosuppressive landscape of pancreatic cancer.

The Journal of clinical investigation·2026

Same journal

Julie Zikherman receives the ASCI/Marian W. Ropes, MD, Award.

The Journal of clinical investigation·2026

Same journal

Targeted degradation of MDM2 overcomes feedback regulation of p53 signaling in Merkel cell carcinoma models.

The Journal of clinical investigation·2026

Same journal

SGLT2 inhibitors enhance ketogenesis by acting as allosteric activators of the mitochondrial enzyme HMGCS2.

The Journal of clinical investigation·2026

Same journal

MDM2 degraders for Merkel cell carcinoma: round peg in a round hole.

The Journal of clinical investigation·2026

See all related articles

Researchers identified autoantibodies against Scl-86 in scleroderma patients, correlating with diffuse disease. This finding may help predict diffuse scleroderma development.

Area of Science:

Immunology
Rheumatology
Molecular Biology

Background:

Connective tissue diseases, such as scleroderma, are characterized by autoantibodies.
Scleroderma is often associated with autoantibodies to nuclear antigens like Scl-70.
The precise nature and diagnostic utility of other scleroderma-associated antigens remain under investigation.

Purpose of the Study:

To investigate the presence and significance of autoantibodies against the Scl-86 antigen in patients with connective tissue diseases.
To explore the relationship between the Scl-86 and Scl-70 antigens.
To evaluate the potential of anti-Scl-86 antibodies as a predictive marker for diffuse scleroderma.

Main Methods:

Immunoblotting technique was used to analyze sera from over 300 patients with connective tissue diseases.

More Related Videos

Using a Laminating Technique to Perform Confocal Microscopy of the Human Sclera

Using a Laminating Technique to Perform Confocal Microscopy of the Human Sclera

Published on: May 6, 2016

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Related Experiment Videos

Last Updated: May 3, 2026

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 24, 2014

Using a Laminating Technique to Perform Confocal Microscopy of the Human Sclera

Using a Laminating Technique to Perform Confocal Microscopy of the Human Sclera

Published on: May 6, 2016

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Sera were tested for autoantibodies against the Scl-86 antigen and anti-Scl-70 antibodies.

Characterization of the Scl-86 antigen's biochemical properties and cellular localization was performed.

Main Results:

Autoantibodies against Scl-86 were detected in 14 out of 33 scleroderma patients, correlating with diffuse scleroderma.
All sera positive for anti-Scl-70 antibodies also contained anti-Scl-86 antibodies.
Scl-86 was identified as an insoluble nuclear protein, distinct from the soluble Scl-70 antigen, suggesting Scl-70 may be a degradation product of Scl-86.
Anti-Scl-86 antibodies were found in sera preceding the clinical diagnosis of diffuse scleroderma.

Conclusions:

The anti-Scl-86 antibody is a potential diagnostic marker for diffuse scleroderma.
The Scl-86 antigen and its antibody may play a role in the pathogenesis or diagnosis of scleroderma.
Anti-Scl-86 antibody screening could aid in predicting the development of diffuse scleroderma.